Eiger Biopharmaceuticals (NASDAQ:EIGR)‘s stock had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies in a note issued to investors on Tuesday. They currently have a $17.00 price target on the biotechnology company’s stock, down from their previous price target of $35.00. Piper Jaffray Companies’ target price would indicate a potential upside of 91.01% from the company’s current price.
Other analysts have also recently issued reports about the company. Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Tuesday, January 9th. Ladenburg Thalmann Financial Services began coverage on Eiger Biopharmaceuticals in a research report on Wednesday, January 3rd. They set a “buy” rating and a $32.00 price target for the company. ValuEngine raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Oppenheimer set a $34.00 price target on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, December 7th. Finally, Wedbush reaffirmed a “buy” rating on shares of Eiger Biopharmaceuticals in a research report on Wednesday, October 25th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $27.25.
Shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) traded up $0.45 during midday trading on Tuesday, reaching $8.90. 475,418 shares of the company traded hands, compared to its average volume of 439,400. The firm has a market cap of $93.60, a P/E ratio of -1.68 and a beta of 2.54. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19. Eiger Biopharmaceuticals has a 1-year low of $6.10 and a 1-year high of $16.20.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.28) by $0.18. research analysts predict that Eiger Biopharmaceuticals will post -4.56 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of EIGR. OxFORD Asset Management LLP acquired a new stake in Eiger Biopharmaceuticals in the third quarter valued at about $147,000. JPMorgan Chase & Co. boosted its position in shares of Eiger Biopharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 8,748 shares during the last quarter. Sphera Funds Management LTD. boosted its position in Eiger Biopharmaceuticals by 35.0% in the third quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock worth $5,723,000 after purchasing an additional 134,968 shares during the last quarter. Wedbush Securities Inc. purchased a new position in Eiger Biopharmaceuticals in the third quarter worth $114,000. Finally, P.A.W. Capital Corp purchased a new position in Eiger Biopharmaceuticals in the third quarter worth $880,000. Hedge funds and other institutional investors own 47.06% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Piper Jaffray Companies Reiterates Overweight Rating for Eiger Biopharmaceuticals (EIGR)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/18/piper-jaffray-companies-reiterates-overweight-rating-for-eiger-biopharmaceuticals-eigr.html.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.